Emerging Gene Therapies in the Fight Against ALS

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), ABIM MOC Points, CE for Pharmacists, AAPA Category I CME Credit

0.75 CME CE: In part 3 of this series, faculty discuss best practices for navigating the clinical trial landscape of ALS gene therapies. Exp 4/12/23

Improving Diagnosis and Clinical Monitoring of Acid Sphingomyelinase Deficiency

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

1.00 CME CE: Experts Drs. Margaret McGovern and Pramod Mistry review the diagnosis and treatment of acid sphingomyelinase deficiency. Exp 5/27/23

Personalized Care of Generalized Myasthenia Gravis: Integrating Novel Targeted Therapies Into Management

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

1.00 CME/CE: 3 neuromuscular experts discuss our evolving understanding of gMG pathogenesis and review rationales for new targeted agents. Exp 12/27/22

On Target with “OFF” Therapies: An Exploration of New Agents and Strategies for Parkinson’s Disease

AMA PRA Category 1 Credit(s)^TM

1.00 CME: Parkinson’s disease specialists review their perspectives on and preferred strategies for the use of new agents to manage OFF episodes. Exp 10/27/22

Migraine Management for the Nurse Practitioner: Acute and Preventive Therapies to Reduce Burden of Disease

ANCC Contact Hour(s), AANP Contact Hour(s)

0.75 CE: 48-minute video designed to improve clinicians’ ability to diagnose and treat migraine in a timely and effective manner. Exp 12/22/2022

Evolving Treatment Approaches for Generalized Myasthenia Gravis to Reduce Disease Burden and Improve Daily Living

AMA PRA Category 1 Credit(s)^TM

1.00 CME: Specific subtypes of gMG and the clinical characteristics, biomarkers, and patient factors essential to optimal treatment decisions. Exp 11/30/22

Multiple Sclerosis Management: Shedding Light on the Patient Perspective

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

1.00 CME/CE: Extensive patient data provide scientific discussion on under-recognized considerations in the long-term management of MS. Exp 12/16/22

Parkinson Disease Tomorrow: Evaluation of New Targets and Formulations

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), AAPA Category I CME Credit

1 CME CE: Safety and efficacy data for emerging treatment of wearing off and how to integrate novel formulations of adjunctive therapies. Exp 1/23/23

Advances in the Management of Parkinson’s Disease-Related Psychosis in Long-Term Care

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

1.00 CME CE: Practical approach to the diagnosis and management of hallucinations and delusions in LTC residents with Parkinson’s disease. Exp 12/31/22

Parkinson Disease Today: Managing Off Symptoms

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), AAPA Category I CME Credit

1.00 CME CE: Discusses underlying mechanisms of off fluctuations, motor and nonmotor off symptoms and their impact on patients, and more. Exp 1/17/23

Advances in Treating Tardive Dyskinesia

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), AAPA Category I CME Credit

1.00 CME CE: John M. Kane, MD, discusses risk factors and contributors to tardive dyskinesia (TD) and approved agents for TD treatments. Exp. 1/19/23

Role of Genetics in ALS: Who Should Be Tested?

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), ABIM MOC Points, CE for Pharmacists, AAPA Category I CME Credit, CE for Psychologist

0.50 CME CE: Join Dr. Andrews and Dr. Al-Chalabi in part 2 of this CME Outfitter’s Snack series as they discuss the utility of genetic testing in ALS. Exp. 3/10/23